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formulation resulted in less erosion from the total brand. In cases where branded 
utilization is not converted to TR formulation prior to launch of generic competition, 
such as risperidone and ﬂuoxetine, or TR launch precedes generic launch by less than 
six months or not at all, such as azythromycin and sertraline, dramatic reduction in 
total sales brand was observed. In the unique case where branded escitalopram was 
introduced prior to the generic launch of citalopram, an effect similar to a branded 
TR launch was observed. CONCLUSIONS: While generic use typically replaces the 
majority of branded equivalents in a short timeframe, branded products with a time-
release formulation may limit uptake rate of the generic version of the total branded 
product.
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OBJECTIVES: Historic data suggest that most 1918 inﬂuenza pandemic-related 
deaths were due to pneumococcal disease (PD); preliminary evidence shows a similar 
pattern for the 2009 H1N1 inﬂuenza outbreak. Implementation of 13-valent pneu-
mococcal conjugate vaccine (PCV13) national immunization programs would likely 
lessen the impact of a pandemic in Asia-Paciﬁc populations that currently have low 
pneumococcal vaccination rates; our objective was to quantify this impact in Singa-
pore and Hong Kong. METHODS: We used a decision-analytic model to assess the 
impact of PCV13 infant vaccination on PD incidence and mortality in an inﬂuenza 
pandemic in Singapore and Hong Kong versus no vaccination. The model was esti-
mated from published sources; both direct and indirect (herd) effects against PD were 
included. Effectiveness of PCV13 was extrapolated from observed US 7-valent PCV 
(PCV7) data, using assumptions on serotype prevalence in the pre-PCV7 era, and 
PCV13 protection against the 6 serotypes not in PCV7. Country-speciﬁc data were 
used where available; where unavailable, US data were used. To simulate acceleration 
of PD transmission in a ﬂu pandemic, we calibrated to 1918 estimates of country-
speciﬁc incidence and mortality, adjusting mortality for the advent of antibiotics. PD 
incidence and mortality, and total PD-related health-care costs were evaluated over a 
1-year horizon. Results are reported in local 2008 currency. RESULTS: Preliminary 
results of the model indicate that in a pandemic of 1918 severity, PCV13 vaccination 
would prevent 3,300 cases of hospitalized pneumococcal pneumonia and 320 deaths 
in Singapore, and save SGD1.53 million in health-care costs (net of vaccination). In 
Hong Kong, PCV13 would prevent 8,200 cases of hospitalized pneumonia (all-cause), 
and 2,200 pneumonia deaths, respectively; PCV13 would save HKD250 million in 
medical costs. CONCLUSIONS: In an inﬂuenza pandemic affecting the Asia-Paciﬁc 
region, infant vaccination with PCV13 would likely be highly effective in reducing 
pandemic-related deaths, PD cases and associated costs.
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ORGANIZATION: University of California San Diego Medical Center (UCSDMC) 
is a 548 bed academic medical center with an average daily census of 368 patients 
and 23,000 annual discharges. UCSDMC has a large regional footprint as it is the 
only academic medical center in the region and serves as the regions burn center and 
high risk obstetrics and neonatal care center. In addition, UCSDMC was the regions 
ﬁrst level 1 trauma unit. Consequently, patients are admitted to UCSDMC with a wide 
variety of medications and insurance coverage. From a medication safety standpoint, 
outpatient maintenance medication is generally not substituted in our hospital. In 
addition, patients are discouraged to bring their own medication into the hospital to 
assure the quality of the medications. These patient population and policy character-
istics make formulary management particularly challenging, as this practice results in 
a constant baseline use of nonformulary outpatient maintenance medications in our 
inpatient patient population. PROBLEM OR ISSUE ADDRESSED: Detecting trends 
in nonformulary prescribing is important as increased use of nonformulary medica-
tions could indicate an important clinical need of this medication. On the other hand, 
increased use of nonformulary medications in therapeutic areas with equivalent but 
less expensive formulary medications, leads to increased costs. We hypothesized that 
analyzing trends in nonformulary prescribing leads to detection of irrational and more 
expensive, nonformulary medications and therefore to cost savings. GOALS: To 
address these issues, we developed a nonformulary medication use monitoring system 
designed to improve formulary adherence by 50% and detect irrational nonformulary 
use at an early stage. OUTCOMES ITEMS USED IN THE DECISION: Formulary 
adherence is deﬁned as the number of nonformulary medication doses billed divided 
by the total number of doses billed. As an example of irrational prescribing detected 
by this system, cost savings associated with reversing nonformulary levalbuterol use 
to formulary albuterol are reported. IMPLEMENTATION STRATEGY: Trends in 
nonformulary use are monitored using daily, monthly and semi-annual reports.—
Daily monitoring is done by the clinical pharmacist. A report that speciﬁes the non-
formulary orders per nursing unit is sent to each pharmacist for follow up. The 
pharmacist evaluates the order for appropriateness and contacts the physician if 
substitution to a formulary alternative is possible. The intervention is recorded in the 
pharmacy information system and compliance is monitored by the pharmacoeconom-
ics specialist.—Monthly monitoring is done by the pharmacoeconomics specialist. The 
results of this monthly analysis are discussed with the Pharmacist-in-Chief and with 
the Chair of the P&T Committee.—Semi-annual reporting is done by the pharmaco-
economics specialist. Trends in nonformulary prescribing over a six month period are 
discussed at the P&T meeting. An action plan is approved to address the ﬁndings. 
RESULTS: The ﬁrst semi-annual nonformulary prescribing report showed a non-
formulary use of 0.26% of billed doses. The most frequently prescribed nonformulary 
medications were: levalbuterol (bronchodilating agent), latanoprost (ocular glaucoma 
agent), pentosan (bladder relief agent) and Mg-Al plus (magnesium supplement). Based 
on this initial report and the lack of formulary alternatives, the P&T committee added 
the latter three agents to the formulary. However, from a cost savings standpoint, the 
use of levalbuterol at our institution was discouraged as this agent has no known 
beneﬁts over our formulary agent albuterol. At the time of the report, levalbuterol 
was almost 4 times more expensive than albuterol. Collaboration with respiratory 
therapy and pulmonology was sought to educate prescribers and pharmacists about 
the therapeutic equivalence of albuterol and levalbuterol. After these interventions, 
the second semi-annual report showed an 80% decrease of nonformulary use to 
0.05% of billed doses. Levalbuterol use decreased by 67% from an average of 24 
patients per month in the 6 month period before the intervention to 8 patients after 
the intervention. Levalbuterol expenditure decreased from $7800 to $1421 over the 
same period and continues to drop, corresponding to an annualized cost avoidance 
of $8000. LESSONS LEARNED: This case study shows that in an environment where 
formulary management is challenging, a nonformulary prescribing monitoring system 
is successful in decreasing nonformulary prescribing and identifying areas of improve-
ment. The large decrease in use of levalbuterol is only one of the successes resulting 
from this effort. However, by implementing continuous monitoring of nonformulary 
prescribing we expect to detect and prevent these excesses in the future. We acknowl-
edge that the monetary savings of decreasing levalbuterol use and nonformulary 
prescribing as a whole is marginal. However, other beneﬁts of a formulary that is 
better tailored to the institution’s needs could include better inventory management, 
improved medication safety and less interruptions of therapy. This will be the focus 
of a subsequent study.
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ORGANIZATION: Premera Blue Cross PROBLEM OR ISSUE ADDRESSED: Tra-
ditional U.S. payer drug selection processes are based on safety, efﬁcacy and drug cost. 
As premiums continue to rise, many plan sponsors have responded by raising member 
cost shares on biologics and other high cost pharmaceuticals. This creates affordability 
barriers for these drugs, regardless of their clinical value, comparative effectiveness or 
cost-effectiveness. GOALS: Our novel cost-effectiveness driven formulary design seeks 
to offset the negative impact of such policies on clinical outcomes and quality of care 
by assigning the drugs that are the most incrementally cost-effective to the lowest 
formulary tiers. OUTCOMES ITEMS USED IN THE DECISION: Comparative effec-
tiveness and safety (clinical beneﬁts and harms as determined by our existing formu-
lary process) and incremental cost-effectiveness ratios of speciﬁc therapies vs. usual 
care alternatives, based on published cost-effectiveness analyses, manufacturer-sub-
mitted cost-effectiveness models and in some cases, models developed internally by 
plan staff. Cost-effectiveness studies are subjected to a quality review process before 
being presented to the formulary committee. IMPLEMENTATION STRATEGY: 
Premera Blue Cross has created a formulary process that assigns each drug to one of 
four tiers based on a set of ﬂexible cost-effectiveness thresholds. Incremental cost-
effectiveness, assessed as rigorously as possible, provides a scientiﬁc, transparent and 
defensible means of maintaining lower cost shares for the highest value drugs, regard-
less of actual prescription cost. In some cases, a drug may fall in more than one tier, 
based on the patient population and the particular indication for which it is being 
used. This presentation describes Premera’s formulary process, how the thresholds for 
each tier were established and how drugs and therapeutic classes are reviewed by an 
external multidisciplinary expert committee, with speciﬁc therapeutic drug class 
outcome examples. This formulary is being offered as part of a new pharmacy beneﬁt 
product addressing a currently unmet market need. RESULTS: Premera’s new formu-
lary process was developed in 2009. This presentation describes the methods used to 
establish incremental cost-effectiveness thresholds for each formulary tier and the 
constitution of an external multidisciplinary expert committee to assign speciﬁc drugs 
to tiers. The rationale and tier assignments for speciﬁc therapeutic drug classes are 
presented as examples. LESSONS LEARNED: Despite limitations to the current avail-
ability of clinical and economic outcomes from well-designed studies on which to base 
tiering decisions, it is possible to implement a credible process based on incremental 
